摘要
目的:探讨原发中枢神经系统淋巴瘤(PCNSL)患者接受放疗与替莫唑胺为主的化疗治疗的效果。方法:按照是否接受放疗将43例PCNSL患者分为实验组(放疗+化疗) 24例和对照组(化疗) 19例,对照组仅接受以替莫唑胺为主的化疗,实验组患者接受同步放化疗治疗,比较两组患者治疗后近期疗效、外周血T淋巴细胞亚群、NK细胞含量,并记录治疗期间毒副反应及5年内患者总生存率(OS)和无进展生存率(PFS)。结果:实验组患者总有效率(RR)显著高于对照组,差异有统计学意义(P <0. 05);实验组患者治疗后CD3+、CD4+、CD4+/CD8+、NK细胞含量均显著高于对照组,CD8+水平显著低于对照组,差异有统计学意义(P <0. 05);实验组患者血液毒性反应、脱发和黏膜炎发生率均显著高于对照组,差异有统计学意义(P <0. 05);实验组患者1年、3年无进展生存率均显著高于对照组,中位生存时间显著长于对照组,差异具有统计学意义(P <0. 05)。结论:放疗联合替莫唑胺为主的化疗治疗PCNSL疗效显著,患者免疫治疗改善明显,远期生存率高,但部分毒副反应发生率有所增加。
Objective:To explore the clinical effects for the patients with primary central nervous system lymphoma by radiation and temozolomide.Methods:43 cases of patients with PCNSL were randomly divided into experiment group(radiation+chemotherapy)and control group(chemotherapy).The clinical effects,peripheral blood T lymphocyte subsets,NK cell content,OS,PFS were compared.Results:The RR for the experiment group were higher than the control group(P﹤0.05);The CD3^+,CD4^+,CD4^+/CD8^+,NK for the experiment group were higher than the control group(P﹤0.05);the CD8+for the experiment group were lower than the control group(P﹤0.05);the rate of blood toxicity reaction,alopecia,mucositis for the experiment group were higher than the control group(P﹤0.05);the PFS for 1 year and 3 years for the experiment group were higher than the control group(P﹤0.05),the median survival time were longer than the control group(P﹤0.05).Conclusion:It has good clinical effects for the patients with primary central nervous system lymphoma by radiation and temozolomide,it can improve the immune function,with high rate of long term survival rate,it has high rate of side effect.
作者
陈泽慧
张跃强
CHEN Zehui;ZHANG Yueqiang(Department of Oncology,Traditional Chinese Medical Hospital of Zhoukou City,He’nan Province 466000)
出处
《医学理论与实践》
2019年第3期316-318,315,共4页
The Journal of Medical Theory and Practice
